Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL-05 T-cell Therapy for Metastatic Melanoma
NCT01271907Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Dec 2011
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CTL-05 in cutaneous melanoma (CM), sponsored by National Cancer Institute. Started Apr 2011; status: terminated.
02
Drugs
CTL-05
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01271907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271907.